{"id":"diammonium-glycyrrhizinate-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Sodium retention"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL4297742","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glycyrrhizinate, the active metabolite of licorice root, acts as a mineralocorticoid and glucocorticoid receptor modulator that inhibits phospholipase A2 and reduces production of inflammatory mediators including TNF-α, IL-6, and IL-8. The diammonium salt formulation improves bioavailability and allows oral capsule delivery for systemic anti-inflammatory and hepatoprotective effects.","oneSentence":"Diammonium glycyrrhizinate reduces inflammation and modulates immune responses by enhancing glucocorticoid receptor signaling and suppressing pro-inflammatory cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:21.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Liver inflammation and hepatic injury"},{"name":"Autoimmune hepatitis"}]},"trialDetails":[{"nctId":"NCT05023915","phase":"PHASE2","title":"A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shandong University","startDate":"2021-08-21","conditions":"Immune Thrombocytopenia","enrollment":106},{"nctId":"NCT05689645","phase":"PHASE2","title":"F573 for Injection for the Treatment of Liver Injury/Failure","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2023-03-24","conditions":"Acute Liver Failure, Acute-On-Chronic Liver Failure","enrollment":97},{"nctId":"NCT07117942","phase":"PHASE2","title":"FDGL Dose-Finding Study for Diabetic Neuropathy","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-02-12","conditions":"Diabetic Neuropathy","enrollment":485},{"nctId":"NCT02961413","phase":"","title":"A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）","status":"RECRUITING","sponsor":"Drug Induced Liver Disease Study Group","startDate":"2016-04","conditions":"Drug-induced Liver Injury","enrollment":10000},{"nctId":"NCT05276895","phase":"NA","title":"Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis","status":"SUSPENDED","sponsor":"Assiut University","startDate":"2022-07-01","conditions":"Osteoarthritis","enrollment":60},{"nctId":"NCT05788705","phase":"NA","title":"Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Adel A.Gomaa","startDate":"2023-07","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT04487964","phase":"NA","title":"Complementary Intervention for COVID-19","status":"COMPLETED","sponsor":"Egyptian Biomedical Research Network","startDate":"2020-01-01","conditions":"COVID-19","enrollment":50},{"nctId":"NCT03306745","phase":"NA","title":"Micronutrient Supplementation in PCO-syndrome","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-06-02","conditions":"Polycystic Ovary Syndrome, Infertility, Female, Micronutrient Deficiency","enrollment":60},{"nctId":"NCT03349008","phase":"PHASE4","title":"Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Cttq","startDate":"2017-11-25","conditions":"Chronic Hepatitis b, Liver Inflammation","enrollment":480},{"nctId":"NCT02473458","phase":"PHASE1, PHASE2","title":"Efficacy of Whole Extract of Licorice in Neurological Improvement of Patients After Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2012-06","conditions":"Acute Stroke","enrollment":75},{"nctId":"NCT01342185","phase":"PHASE3","title":"Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2010-03","conditions":"Chronic Hepatitis B","enrollment":189}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ganlixin capsules"],"phase":"phase_3","status":"active","brandName":"Diammonium glycyrrhizinate Capsules","genericName":"Diammonium glycyrrhizinate Capsules","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diammonium glycyrrhizinate reduces inflammation and modulates immune responses by enhancing glucocorticoid receptor signaling and suppressing pro-inflammatory cytokine production. Used for Chronic hepatitis B, Liver inflammation and hepatic injury, Autoimmune hepatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}